Evidence map›Paper›PMID 34930545›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021

Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs.

Alex H Gifford, Thida Ong, Christopher Dowd, Aricca D Van Citters, Peter Scalia, Kathryn A Sabadosa, Gregory S Sawicki

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Impact of COVID-19 in Children with Chronic Lung Diseases.International journal of environmental research and public health · 2022
    Review
  13. The Impact of COVID-19 in Cystic Fibrosis.Archivos de bronconeumologia · 2022
    Article
  14. Review
  15. A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022
    Review
  16. Design and methods for understanding the state of cystic fibrosis care amid the COVID-19 pandemic.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Alex H GiffordPulmonary Critical Care and Sleep Medicine, University Hospitals, Cleveland, OH, USA. Electronic address: Alex.Gifford@UHhospitals.org.
Thida OngPediatric Pulmonology, Seattle Children's Hospital, Seattle, WA, USA.
Christopher DowdCystic Fibrosis Foundation, Bethesda, MD, USA.
Aricca D Van CittersThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Peter ScaliaThe Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Kathryn A SabadosaCystic Fibrosis Foundation, Bethesda, MD, USA.
Gregory S SawickiDivision of Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
Cystic Fibrosis Foundation · USDartmouth Institute for Health Policy and Clinical Practice · USBoston Children's Hospital · USSeattle Children's Hospital · USUniversity Hospitals of Cleveland · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystic fibrosis (CF) care programs in the United States rapidly adopted telehealth during the COVID-19 pandemic. Understanding factors that promote or impede telehealth will inform planning for future telehealth-enabled care models.

methodsAdult, pediatric, and affiliate CF care programs in the United States (n = 287) were surveyed twice eight months apart in 2020-2021 about telehealth use. Programs were asked to describe barriers to and promoters of telehealth.

resultsNinety-seven percent of programs provided telehealth services. In the first CF Care Program State of Care Survey (SoC1), programs estimated that 57% of patients exclusively received in-person care, 36% of patients received telehealth by phone/computer with video, and 8% of patients received telephone-only care. In the second CF Care Program State of Care Survey (SoC2), programs estimated that 80% of visits were in-person and 15% were via audio and video telehealth. Pediatric programs (21%) were less likely than adult (37%) or affiliate (41%) programs to recommend telehealth (p = 0.007). All programs ranked lack of internet access as the highest barrier to patient engagement with telehealth. Promoters of telehealth were increased accessibility and avoidance of infection transmission. Top ranked changes to improve telehealth were expanded provision of remote monitoring devices and technology access. Similar proportions of program types anticipated institutional telehealth expansion.

conclusionDuring the COVID-19 pandemic, CF programs in the United States identified factors to improve future care delivery via telehealth. Targeting specific barriers and promoters will improve the use and quality of telehealth throughout the care center network.

Indexed as

Communication BarriersCOVID-19Cystic FibrosisHealth Services AccessibilityPatient ParticipationTelemedicineAdultChildDisease Transmission, InfectiousFemaleHumansInternet AccessMaleNeeds AssessmentPatient SatisfactionQuality ImprovementCOVID-19Cystic fibrosisPandemicTelehealth

Identifiers

PMID34930545
PMCPMC8683125
OpenAlexW4200142780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.